The greatest rate of treatment persistence in patients with psoriasis following MACE was seen in those receiving biologics vs other treatment types.
Topline data were announced from 2 replicate phase 3 studies evaluating upadacitinib in adults and adolescents with nonsegmental vitiligo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback